A Phase 1 interventional study of Lenvatinib and Nivolumab in Carcinoma, Hepatocellular, sponsored by Eisai Co., Ltd.. Completed at 6 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-06-20.
Sponsored by Eisai Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 121 studies testing lenvatinib in Carcinoma, Hepatocellular — 57 open to participants now, 65 under way, 7 of them phase 3. lenvatinib · Carcinoma, Hepatocellular.
Among the 121 studies testing lenvatinib in Carcinoma, Hepatocellular, this one is the 89th largest by enrollment, is one of 6 that started in 2018, is one of 9 in phase 1, and was the 5th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.
Browse Carcinoma, Hepatocellular studies →57 of the 121 studies testing lenvatinib in Carcinoma, Hepatocellular are open now, in 6 countries. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
First Hospital of China Medical University · Sites in China
Ages 18–80
National Cancer Center, Korea · Sites in Korea, Republic of
Ages 19–79
By country, each count listing its studies:
lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lenvatinib is the treatment under test here. Read study by study →
121 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 79 · Phase 3 17 · Phase 4 5
First in 2009; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 54 across 2,619 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 48 across the 121 interventional studies. Of the 21 that completed or were terminated, 6 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 121 have an industry lead sponsor. The 10 most frequent:
Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
20 studies in Carcinoma, Hepatocellular by Eisai Co., Ltd.: none open now, 4 under way, none of them phase 3. Of 16 finished, 8 (50%) have results posted.
Among the 20 studies in Carcinoma, Hepatocellular by Eisai Co., Ltd., this one is the 12th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2018, is one of 6 in phase 1, and was the 10th registered.
Eisai Co., Ltd.’s Carcinoma, Hepatocellular studies by the year they started, since 2004.
14 of the studies testing lenvatinib in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06041477Phase 3Sun Yat-sen UniversityConcurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC | 2027-07 |
| NCT05621499Tianjin Medical University Cancer Institute and HospitalHAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma | 2026-11 |
| NCT07081633AstraZenecaDurvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | 2026-11-30 |
| NCT04615143Sun Yat-sen UniversityTislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC | 2026-12-01 |
| NCT06524466Sun Yat-sen UniversityNeoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma | 2026-12-01 |
Add all 14 to your calendar (.ics) → With an account.
Among the 121 studies testing lenvatinib in Carcinoma, Hepatocellular, from their registry updates:
Among Eisai Co., Ltd.’s 20 in Carcinoma, Hepatocellular:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the tolerability and safety of a combination of lenvatinib plus nivolumab in participants with hepatocellular carcinoma (HCC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have confirmed diagnosis of hepatocellular carcinoma (HCC) with any of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive specified doses of lenvatinib (oral) and nivolumab (intravenous) on specified days.
Drug: Lenvatinib · Drug: Nivolumab
If tolerable in Part 1, participants will receive specified doses of lenvatinib and nivolumab on specified days until criteria for discontinuation are met.
Drug: Lenvatinib · Drug: Nivolumab
Specified doses will be administered orally on specified days.
Specified doses will be administered intravenously on specified days.
Part 1: Number of Participants With Dose-Limiting Toxicities (DLTs)
DLT was graded according to Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03). DLT was defined as any of the following hematological or non-hematological toxicities considered to be at least possibly related to lenvatinib and/or nivolumab occurring during Cycle 1: 1) Febrile neutropenia or Grade 4 neutropenia for \>7 days; 2) Grade 4 thrombocytopenia and Grade 3 thrombocytopenia with bleeding; 3) Grade 4 anemia; 4) Clinical deterioration manifested by drug-related hepatic decompensation; 5) \>=Grade 3 non-hematological laboratory abnormalities with clinical symptoms that persisted; 6) Other Grade 3 toxicity lasting \>3 days or Grade 4 non-hematological toxicity of any duration; 7) Grade 2 uveitis, eye pain, or blurred vision that did not respond to topical therapy; 8) Failure to administer 8 or more dose of the planned administration number of study drug in Cycle 1 as a result of treatment-related toxicity.
Time frame: Cycle 1 (Cycle length = 28 days)
Part 1 and Part 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
A TEAE was defined as an adverse event (AE) that emerged during treatment and until the 30 days after the last dose or until the participants initiated new anticancer therapy, whichever was earlier, was absent at pretreatment (Baseline) or reemerged during treatment, was present at pretreatment (Baseline) but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the AE was continuous. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening (that is, participant was at immediate risk of death from AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug).
Time frame: From the first dose of study drug until 30 days after the last dose (up to 53 months)
Mean Change From Baseline in Vital Sign: Weight
Mean change from baseline in weight were evaluated.
Time frame: Baseline, up to Month 53
Mean Change From Baseline in Vital Sign: Body Mass Index
Mean change from baseline in body mass index were evaluated.
Time frame: Baseline, up to Month 53
Mean Change From Baseline in Vital Sign: SpO2 (Oxygen Saturation)
Mean change from baseline in SpO2 were evaluated.
Time frame: Baseline, up to Month 53
Number of Participants With Treatment-Emergent Markedly Abnormal Laboratory Values (TEMAVs)
Treatment-emergent markedly abnormal laboratory value was defined as a postbaseline laboratory value with grade 3 or higher, and with a grade increase from baseline, (that is \[i.e.\] increasing grade 0 to 3 or higher, grade 1 to 3 or higher, grade 2 to 3 or higher, grade 3 to 4 or 5, grade 4 to 5). Test abnormalities were graded by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 as Grade 1 =mild; Grade 2 =moderate; Grade 3/Grade 4 =severe/life-threatening, Grade 5 =death.
Time frame: From the first dose of study drug until 30 days after the last dose (up to 53 months)
Number of Participants With Highest Post-Baseline Values for Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Scale
Performance status assessments were based on 5-grade ECOG scale (from 0 to 4), where 0=fully active, able to carry on all pre-disease performance without restriction; 1=restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (e.g., light house work, office work); 2=ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours; 3=capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed or chair; 5=dead.
Time frame: Baseline, up to Month 53
Change From Baseline in Left Ventricular Ejection Fraction (LVEF)
Change from baseline in left ventricular ejection fraction (LVEF) were evaluated by multigated acquisition scan (MUGA) or echocardiogram.
Time frame: Baseline, up to Month 53
Part 1 and Part 2: Objective Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST) Assessed by Investigator Review
ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) based on mRECIST assessed by investigator review. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is less than 10 millimeters \[mm\] if it exists in a lymph node). PR defined as at least 30% decrease in the sum of diameter of all target lesions without unequivocal progression of all non-target lesions, as compared with Baseline.
Time frame: From the first dose of study drug to the first date of documentation of PD or death, whichever occurred first (up to 52 months)
Part 1, Cmax: Maximum Observed Plasma Concentration for Lenvatinib
Cmax was defined as the maximum plasma concentration for lenvatinib. Cmax was derived by non-compartmental analysis using lenvatinib plasma concentrations.
Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)
Part 1, Tmax: Time to Reach the Cmax for Lenvatinib
Tmax was defined as the time to reach maximum observed plasma concentration (Cmax) for lenvatinib. Tmax was derived by non-compartmental analysis using lenvatinib plasma concentrations.
Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)
Part 1, AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero Time to the Last Measurable Point for Lenvatinib
AUC(0-t) was defined as the area under the plasma concentration-time curve from 0 time to last measurable point for lenvatinib. AUC(0-t) was derived by non-compartmental analysis using lenvatinib plasma concentrations.
Time frame: Cycle 1 Day 1 and Day 15: 0-24 hours post-dose (Cycle length=28 days)
Part 1, AUC(0-Inf): Area Under the Plasma Concentration-time Curve From Zero to Infinity for Lenvatinib
AUC(0-Inf) was defined as the area under the plasma concentration-time curve from 0 to infinity for lenvatinib. AUC(0-Inf) was derived by non-compartmental analysis using lenvatinib plasma concentrations.
Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)
Part 1, t1/2: Terminal Elimination Phase Half-Life for Lenvatinib
t1/2 was defined as the terminal elimination phase half-life for lenvatinib. t1/2 was derived by non-compartmental analysis using lenvatinib plasma concentrations.
Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)
Part 1, CL/F: Apparent Total Clearance for Lenvatinib
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as (Dose/AUC(0-inf))/F. Where AUC(0-inf) is the area under the plasma concentration-time curve from zero to infinity and F is the bioavailability of the drug.
Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)
Part 1, Vz/F: Apparent Terminal Volume of Distribution for Lenvatinib
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was calculated as (CL/F)/Lambda Z. Where, CL/F is the apparent total clearance and lambda Z is the apparent terminal elimination rate constant.
Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)
Part 1, Css,Max: Maximum Observed Plasma Concentration at Steady State for Lenvatinib
Css,max was defined as the maximum plasma concentration at steady state for lenvatinib. Css,max was derived by non-compartmental analysis using lenvatinib plasma concentrations.
Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=28 days)
Part 1, Css,Min: Minimum Observed Plasma Concentration at Steady State for Lenvatinib
Css,min is the minimum plasma concentration at steady state for lenvatinib. Css,min was derived by non-compartmental analysis using lenvatinib plasma concentrations.
Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=28 days)
Part 1, Tss,Max: Time to Maximum Observed Concentration at Steady State For Lenvatinib
Tss,Max was defined as the time to reach maximum observed plasma concentration of lenvatinib at steady state. Tss,Max was derived by non-compartmental analysis using lenvatinib plasma concentrations.
Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=28 days)
Part 1, Rac (Cmax): Accumulation Ratio of Cmax for Lenvatinib
Rac(Cmax) was calculated as Css,max at Cycle 1 Day 15/Cmax at Cycle 1 Day 1.
Time frame: Cycle 1 Day 1 and Day 15: 0-24 hours post-dose (Cycle length=28 days)
Part 1, Rac (AUC0-t): Accumulation Ratio of AUC(0-t) for Lenvatinib
Rac(AUC) was calculated as AUC(0-t) at Cycle 1 Day 15/AUC(0-t) at Cycle 1 Day 1.
Time frame: Cycle 1 Day 1 and Day 15: 0-24 hours post-dose (Cycle length=28 days)
Part 1, MRT: Mean Residence Time for Lenvatinib
MRT was derived by non-compartmental analysis using lenvatinib plasma concentrations.
Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)
The study was conducted in two parts (Part 1 and Part 2) between 16 January 2018 and 28 December 2022 at 1 site for Part 1 and 6 sites for Part 2 in Japan.
| Milestone | Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | Part 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg |
|---|---|---|
| Started | 6 | 24 |
| Completed | 4 | 18 |
| Not completed | 2 | 6 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
DLT was graded according to Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03). DLT was defined as any of the following hematological or non-hematological toxicities considered to be at least possibly related to lenvatinib and/or nivolumab occurring during Cycle 1: 1) Febrile neutropenia or Grade 4 neutropenia for \>7 days; 2) Grade 4 thrombocytopenia and Grade 3 thrombocytopenia with bleeding; 3) Grade 4 anemia; 4) Clinical deterioration manifested by drug-related hepatic decompensation; 5) \>=Grade 3 non-hematological laboratory abnormalities with clinical symptoms that persisted; 6) Other Grade 3 toxicity lasting \>3 days or Grade 4 non-hematological toxicity of any duration; 7) Grade 2 uveitis, eye pain, or blurred vision that did not respond to topical therapy; 8) Failure to administer 8 or more dose of the planned administration number of study drug in Cycle 1 as a result of treatment-related toxicity.
| Participants | Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg |
|---|---|
| Part 1: Number of Participants With Dose-Limiting Toxicities (DLTs) | 0 |
A TEAE was defined as an adverse event (AE) that emerged during treatment and until the 30 days after the last dose or until the participants initiated new anticancer therapy, whichever was earlier, was absent at pretreatment (Baseline) or reemerged during treatment, was present at pretreatment (Baseline) but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the AE was continuous. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening (that is, participant was at immediate risk of death from AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug).
| Participants | Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | Part 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg |
|---|---|---|
| TEAEs | 6 | 24 |
| SAEs | 3 | 12 |
Mean change from baseline in weight were evaluated.
| kilogram | Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | Part 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg |
|---|---|---|
| Mean Change From Baseline in Vital Sign: Weight | 2.82 ± 3.931 | -3.10 ± 4.953 |
Mean change from baseline in body mass index were evaluated.
| kilogram per square meter | Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | Part 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg |
|---|---|---|
| Mean Change From Baseline in Vital Sign: Body Mass Index | 1.10 ± 1.434 | -1.12 ± 1.811 |
Mean change from baseline in SpO2 were evaluated.
| percentage of blood oxygen saturation | Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | Part 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg |
|---|---|---|
| Mean Change From Baseline in Vital Sign: SpO2 (Oxygen Saturation) | 0.2 ± 0.75 | -0.6 ± 1.41 |
Treatment-emergent markedly abnormal laboratory value was defined as a postbaseline laboratory value with grade 3 or higher, and with a grade increase from baseline, (that is \[i.e.\] increasing grade 0 to 3 or higher, grade 1 to 3 or higher, grade 2 to 3 or higher, grade 3 to 4 or 5, grade 4 to 5). Test abnormalities were graded by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 as Grade 1 =mild; Grade 2 =moderate; Grade 3/Grade 4 =severe/life-threatening, Grade 5 =death.
| Participants | Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | Part 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg |
|---|---|---|
| Hemoglobin: Markedly Abnormal Low | 0 | 2 |
| Hemoglobin: Markedly Abnormal High | 0 | 0 |
| Platelets: Markedly Abnormal Low | 2 | 1 |
| Leukocytes: Markedly Abnormal Low | 0 | 0 |
| Leukocytes: Markedly Abnormal High | 0 | 0 |
| Lymphocytes: Markedly Abnormal Low | 2 | 4 |
| Lymphocytes: Markedly Abnormal High | 0 | 0 |
| Neutrophils: Markedly Abnormal Low | 0 | 3 |
| Prothrombin international normalized ratio: Markedly Abnormal High | 0 | 0 |
| Alkaline phosphatase: Markedly Abnormal High | 0 | 1 |
| Aspartate aminotransferase: Markedly Abnormal High | 0 | 6 |
| Alanine aminotransferase: Markedly Abnormal High | 1 | 1 |
| Gamma-glutamyl transferase: Markedly Abnormal High | 1 | 6 |
| Bilirubin: Markedly Abnormal High | 0 | 3 |
| Creatinine: Markedly Abnormal High | 1 | 0 |
| Glucose: Markedly Abnormal Low | 0 | 0 |
| Glucose: Markedly Abnormal High | 0 | 4 |
| Albumin: Markedly Abnormal Low | 1 | 2 |
| Cholesterol: Markedly Abnormal High | 0 | 0 |
| Triglycerides: Markedly Abnormal High | 0 | 1 |
| Phosphate: Markedly Abnormal Low | 0 | 3 |
| Sodium: Markedly Abnormal Low | 0 | 3 |
| Sodium: Markedly Abnormal High | 0 | 0 |
| Potassium: Markedly Abnormal Low | 0 | 3 |
| Potassium: Markedly Abnormal High | 0 | 0 |
| Calcium corrected: Markedly Abnormal Low | 0 | 0 |
| Calcium corrected: Markedly Abnormal High | 0 | 0 |
| Magnesium: Markedly Abnormal Low | 0 | 1 |
| Magnesium: Markedly Abnormal High | 0 | 0 |
| Amylase: Markedly Abnormal High | 1 | 1 |
| Lipase: Markedly Abnormal High | 3 | 5 |
Performance status assessments were based on 5-grade ECOG scale (from 0 to 4), where 0=fully active, able to carry on all pre-disease performance without restriction; 1=restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (e.g., light house work, office work); 2=ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours; 3=capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed or chair; 5=dead.
| Participants | Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | Part 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg |
|---|---|---|
| Grade 0 | 0 | 15 |
| Grade 1 | 5 | 6 |
| Grade 2 | 0 | 1 |
| Grade 3 | 1 | 2 |
| Grade 4 | 0 | 0 |
Change from baseline in left ventricular ejection fraction (LVEF) were evaluated by multigated acquisition scan (MUGA) or echocardiogram.
| %LVEF | Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | Part 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg |
|---|---|---|
| Change From Baseline in Left Ventricular Ejection Fraction (LVEF) | 0.0 ± 2.00 | 0.4 ± 4.65 |
ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) based on mRECIST assessed by investigator review. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is less than 10 millimeters \[mm\] if it exists in a lymph node). PR defined as at least 30% decrease in the sum of diameter of all target lesions without unequivocal progression of all non-target lesions, as compared with Baseline.
| percentage of participants | Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | Part 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg |
|---|---|---|
| Part 1 and Part 2: Objective Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST) Assessed by Investigator Review | 66.7 (22.3 to 95.7) | 79.2 (57.8 to 92.9) |
Cmax was defined as the maximum plasma concentration for lenvatinib. Cmax was derived by non-compartmental analysis using lenvatinib plasma concentrations.
| nanogram per milliliter (ng/mL) | Lenvatinib 8 mg + Nivolumab 240 mg | Lenvatinib 12 mg + Nivolumab 240 mg |
|---|---|---|
| Part 1, Cmax: Maximum Observed Plasma Concentration for Lenvatinib | 93.3 ± 16.8 | 122 ± 46.3 |
Tmax was defined as the time to reach maximum observed plasma concentration (Cmax) for lenvatinib. Tmax was derived by non-compartmental analysis using lenvatinib plasma concentrations.
| hours | Lenvatinib 8 mg + Nivolumab 240 mg | Lenvatinib 12 mg + Nivolumab 240 mg |
|---|---|---|
| Part 1, Tmax: Time to Reach the Cmax for Lenvatinib | 1.45 (0.87 to 2.02) | 3.97 (1.80 to 7.52) |
AUC(0-t) was defined as the area under the plasma concentration-time curve from 0 time to last measurable point for lenvatinib. AUC(0-t) was derived by non-compartmental analysis using lenvatinib plasma concentrations.
| nanogram*hour per milliliter (ng*h/mL) | Lenvatinib 8 mg + Nivolumab 240 mg | Lenvatinib 12 mg + Nivolumab 240 mg |
|---|---|---|
| Cycle 1 Day 1 | 882 ± 0.0801 | 1380 ± 36.0 |
| Cycle 1 Day 15 | 1410 ± 16.7 | 1920 ± 17.2 |
AUC(0-Inf) was defined as the area under the plasma concentration-time curve from 0 to infinity for lenvatinib. AUC(0-Inf) was derived by non-compartmental analysis using lenvatinib plasma concentrations.
| ng*h/mL | Lenvatinib 8 mg + Nivolumab 240 mg | Lenvatinib 12 mg + Nivolumab 240 mg |
|---|---|---|
| Part 1, AUC(0-Inf): Area Under the Plasma Concentration-time Curve From Zero to Infinity for Lenvatinib | 987 ± 6.10 | 1630 ± NA |
t1/2 was defined as the terminal elimination phase half-life for lenvatinib. t1/2 was derived by non-compartmental analysis using lenvatinib plasma concentrations.
| hours | Lenvatinib 8 mg + Nivolumab 240 mg | Lenvatinib 12 mg + Nivolumab 240 mg |
|---|---|---|
| Part 1, t1/2: Terminal Elimination Phase Half-Life for Lenvatinib | 6.77 ± 27.1 | 8.95 ± NA |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as (Dose/AUC(0-inf))/F. Where AUC(0-inf) is the area under the plasma concentration-time curve from zero to infinity and F is the bioavailability of the drug.
| liter per hour (L/h) | Lenvatinib 8 mg + Nivolumab 240 mg | Lenvatinib 12 mg + Nivolumab 240 mg |
|---|---|---|
| Part 1, CL/F: Apparent Total Clearance for Lenvatinib | 8.09 ± 6.30 | 7.37 ± NA |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was calculated as (CL/F)/Lambda Z. Where, CL/F is the apparent total clearance and lambda Z is the apparent terminal elimination rate constant.
| liter | Lenvatinib 8 mg + Nivolumab 240 mg | Lenvatinib 12 mg + Nivolumab 240 mg |
|---|---|---|
| Part 1, Vz/F: Apparent Terminal Volume of Distribution for Lenvatinib | 79.0 ± 20.4 | 95.1 ± NA |
Css,max was defined as the maximum plasma concentration at steady state for lenvatinib. Css,max was derived by non-compartmental analysis using lenvatinib plasma concentrations.
| ng/mL | Lenvatinib 8 mg + Nivolumab 240 mg | Lenvatinib 12 mg + Nivolumab 240 mg |
|---|---|---|
| Part 1, Css,Max: Maximum Observed Plasma Concentration at Steady State for Lenvatinib | 139 ± 29.5 | 164 ± 9.93 |
Css,min is the minimum plasma concentration at steady state for lenvatinib. Css,min was derived by non-compartmental analysis using lenvatinib plasma concentrations.
| ng/mL | Lenvatinib 8 mg + Nivolumab 240 mg | Lenvatinib 12 mg + Nivolumab 240 mg |
|---|---|---|
| Part 1, Css,Min: Minimum Observed Plasma Concentration at Steady State for Lenvatinib | 13.5 ± 15.8 | 28.2 ± 48.7 |
Tss,Max was defined as the time to reach maximum observed plasma concentration of lenvatinib at steady state. Tss,Max was derived by non-compartmental analysis using lenvatinib plasma concentrations.
| hours | Lenvatinib 8 mg + Nivolumab 240 mg | Lenvatinib 12 mg + Nivolumab 240 mg |
|---|---|---|
| Part 1, Tss,Max: Time to Maximum Observed Concentration at Steady State For Lenvatinib | 3.94 (3.85 to 4.02) | 3.93 (3.92 to 7.98) |
Rac(Cmax) was calculated as Css,max at Cycle 1 Day 15/Cmax at Cycle 1 Day 1.
| ratio | Lenvatinib 8 mg + Nivolumab 240 mg | Lenvatinib 12 mg + Nivolumab 240 mg |
|---|---|---|
| Part 1, Rac (Cmax): Accumulation Ratio of Cmax for Lenvatinib | 1.48 ± 12.4 | 1.28 ± 62.4 |
Rac(AUC) was calculated as AUC(0-t) at Cycle 1 Day 15/AUC(0-t) at Cycle 1 Day 1.
| ratio | Lenvatinib 8 mg + Nivolumab 240 mg | Lenvatinib 12 mg + Nivolumab 240 mgEdit |
|---|---|---|
| Part 1, Rac (AUC0-t): Accumulation Ratio of AUC(0-t) for Lenvatinib | 1.59 ± 17.0 | 1.38 ± 47.1 |
MRT was derived by non-compartmental analysis using lenvatinib plasma concentrations.
| hours | Lenvatinib 8 mg + Nivolumab 240 mg | Lenvatinib 12 mg + Nivolumab 240 mg |
|---|---|---|
| Part 1, MRT: Mean Residence Time for Lenvatinib | 10.9 (9.35 to 12.4) | 13.7 (13.7 to 13.7) |
Collected over From the first dose of study drug until 30 days after the last dose (up to 53 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | 1/6 (16.7%) | 3/6 (50%) | 6/6 (100%) |
| Part 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | 18/24 (75%) | 12/24 (50%) | 24/24 (100%) |
| Event | Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | Part 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg |
|---|---|---|
| HyperthyroidismEndocrine disorders | 1/6 | 0/24 |
| DiarrhoeaGastrointestinal disorders | 1/6 | 0/24 |
| BronchitisInfections and infestations | 1/6 | 0/24 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 1/6 | 0/24 |
| Hepatic encephalopathyNervous system disorders | 0/6 | 2/24 |
| LymphadenitisBlood and lymphatic system disorders | 0/6 | 1/24 |
| Adrenal insufficiencyEndocrine disorders | 0/6 | 1/24 |
| Adrenocorticotropic hormone deficiencyEndocrine disorders | 0/6 | 1/24 |
| OedemaGeneral disorders | 0/6 | 1/24 |
| Oedema peripheralGeneral disorders | 0/6 | 1/24 |
| Event | Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | Part 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg |
|---|---|---|
| FatigueGeneral disorders | 5/6 | 4/24 |
| DiarrhoeaGastrointestinal disorders | 4/6 | 15/24 |
| NauseaGastrointestinal disorders | 4/6 | 4/24 |
| Decreased appetiteMetabolism and nutrition disorders | 4/6 | 11/24 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 2/6 | 16/24 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 3/6 | 13/24 |
| HypothyroidismEndocrine disorders | 3/6 | 7/24 |
| ProteinuriaRenal and urinary disorders | 3/6 | 11/24 |
| HypertensionVascular disorders | 1/6 | 10/24 |
| MalaiseGeneral disorders | 0/6 | 9/24 |
Safety analysis set included all participants who received at least 1 dose of lenvatinib or nivolumab.
| Age, Continuous(Years) | Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | Part 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | Total |
|---|---|---|---|
| Mean | 73.5 ± 1.87 | 67.1 ± 10.74 | 68.4 ± 9.94 |
| Sex: Female, Male(Participants) | Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | Part 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | Total |
|---|---|---|---|
| Female | 1 | 5 | 6 |
| Male | 5 | 19 | 24 |
| Race/Ethnicity, Customized(Participants) | Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | Part 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg | Total |
|---|---|---|---|
| Japanese | 6 | 23 | 29 |
| Chinese | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2018 to primary completion in Dec 2022, 59 months.
Results were first posted in Jun 2024, 1 year 5 months after primary completion.
Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 59 months is above that.
Counting every sponsor, half of 248 studies reached it within 49 months; a quarter within 32 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenvatinib · Nivolumab